Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website


AstraZeneca reported $3.2B in Selling and Administration Expenses for its fiscal quarter ending in March of 2023.

Selling And Administration Expenses Change
AbbVie ABBV:US USD 3B 217M
Alcon AG ALC:SW USD 785M 23M
Almirall SA ALM:SM EUR 124.2M 4.84M
Amgen AMGN:US USD 1.26B 210M
AstraZeneca AZN:LN USD 3.2B 331M
Bayer BAYN:GR EUR 4.05B 374M
Biogen BIIB:US USD 605M 27.8M
Bristol-Myers Squibb BMY:US USD 1.76B 504M
Eli Lilly LLY:US USD 1.75B 106M
Fresenius FRE:GR EUR 1.53B 294M
Fresenius Medical Care FME:GR EUR 782M 172.3M
Galapagos GLPG:NA EUR 58.1M 16.58M
Genmab GEN:DC DKK 676M 245M
Gilead Sciences GILD:US USD 1.32B 702M
GlaxoSmithKline GSK:LN GBP 2.06B 370M
Hikma Pharmaceutical HIK:LN USD 253M 3M
Merck MRK:GR EUR 1.47B 103M
Merck & Co MRK:US USD 2.46B 209M
Novartis NOVN:VX USD 3.4B 298M
Orion ORNBV:FH EUR 71.6M 5.4M
Pfizer PFE:US USD 3.49B 1.39B
Philips PHIA:NA EUR 1.24B 238M
Recordati REC:IM EUR 150.43M 9.96M
Regeneron Pharmaceuticals REGN:US USD 601.1M 59.4M
Roche Holding ROG:VX CHF 6.48B 834M